

The opinion in support of the decision being entered today was not written for publication and is not binding precedent of the Board.

Paper No. 32

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES

Ex parte DAVID WALLACH and
CORD BRAKEBUSCH

Appeal No. 1999-0197
Application No. 08/054,970

HEARD: May 24, 2001

Before WILLIAM F. SMITH, SCHEINER, and MILLS, Administrative Patent Judges.

WILLIAM F. SMITH, Administrative Patent Judge.

DECISION ON APPEAL

This is a decision on appeal under 35 U.S.C. § 134 from the examiner's final rejection of claims 34 through 38, 40, 42 through 44, 47 through 52, 54, 56, 57, and 60. Claims 39, 41, 45, 46, 49, 53, 55, 58, and 59 are pending but have been withdrawn from consideration by the examiner. Claims 34, 37, 42, 43, 44, and 60 are representative of the subject matter on appeal and read as follows:

34. A method of inhibiting signal transduction in tumor necrosis factor receptors (TNF-Rs), comprising:

identifying a molecule which binds to the portion of TNF-R which includes Ser197 or the amino acids 405 to 415 of human p55-TNF-R (SEQ ID NO:2) or the corresponding amino acids of the human p75-TNF-R, and thereby causes the signal transduction of said receptor to be inhibited; and

bringing said molecule into contact with said portion of TNF-R.

37. A method for identifying molecules which interact with TNF-R to modulate signal transduction by the TNF-R, comprising:

a) preparing a target peptide which includes amino acids 405-415 of human p55-TNF-R (SEQ ID NO:2) or the corresponding amino acids of human p75-TNF-R;

b) screening peptide libraries and/or broth of biological matter with said target peptide and identifying any molecules which bind to said target peptide; and

c) screening any molecules identified in step b) for their ability to modulate signal transduction of TNF-R and identifying any molecule which tests positive for such signal transduction modulation.

42. A method of inhibiting signal transduction in tumor necrosis factor receptors (TNF-Rs), comprising:

identifying a molecule which reacts with TNF-R to modulate signal transduction by the TNF-R, by means of a process in accordance with claim 37; and

bringing said molecule into contact with the portion of TNF-R which includes amino acids of human p75-TNF-R.

43. A method in accordance with claim 37, for identifying a molecule which interacts with TNF-R to inhibit signal transduction by the TNF-R, wherein said step c) comprises screening any molecules identified in step b) for their ability to inhibit signal transduction of TNF-R and identifying any molecule which tests positive for such signal transduction inhibition.

44. A method for preventing or treating a disease caused by tumor necrosis factor, comprising administering a molecule identifiable by the process of claim 43 in a manner by which said molecule can come into contact with the portion of the p55-TNF-R (SEQ ID NO:2) which includes Ser197 or amino acids 405-415, or the corresponding amino acids of human p75-TNF-R, in an amount effective to prevent or treat said disease.

60. A method for modulating the cleavage of the soluble form of TNF-R from TNF-R, comprising:

obtaining an antibody that binds to the human p55-TNF-R in the region of amino acids 170-174, 175-179 or 170-179 of human p55-TNF-R (SEQ ID NO:2) in a manner such that cleavage of the soluble form of TNF-R from the TNF-R is inhibited; and

bringing said antibody into contact with the portion of said TNF-R to which said antibody is specific.

The examiner does not rely upon prior art in rejecting the claims in the Examiner's Answer.

Claims 34 through 38, 40, 42 through 44, 47 through 52, 54, 56, 57, and 60 stand rejected under 35 U.S.C. § 112, first paragraph (enablement). We reverse and raise other issues for the examiner and appellants to consider.

Background

The claimed invention involves tumor necrosis factor receptors. As explained in the second full paragraph of page 1 of the specification:

TNF, a pro-inflammatory cytokine produced primarily by macrophages, contributes to the defense of the host against pathogens as well as to various detrimental manifestations of inflammation through a variety of different effects on cell function (Old, 1990; Beutler and Cerami, 1989). These effects are initiated by the binding of TNF to specific, high affinity cell surface receptors (TNF-Rs), expressed on most kinds of cells (Baglioni et al., 1985; Beutler et al., 1985; Kull et al., 1985; Tsujimoto et al., 1985; Aggarwal et al., 1985; Israel et al., 1986). The receptors provide the

intracellular signals for cell response to TNF (Englemann et al., 1990a). Two molecular species of the TNF-Rs, the p55 and the p75 TNF-R, expressed differentially in different types of cells, have been identified (Englemann et al., 1990b; Brockhaus et al., 1990).

Appellants also explain on page 2 of the specification that:

The main mediator for the cytotoxic effect of the TNF on fibroblastoid and epithelial cells is the p55 TNF-R, which also is the prevalent TNF-R type on these cell lines. Blocking this receptor species abolishes the cytotoxic effect of TNF, while inducing aggregation of the receptor molecules can mimic the cytotoxic effect of the TNF.

The soluble form of this receptor, as well as the soluble form of the other (p75) TNF-R, have been shown to have inhibitory effects on TNF function. Evidence was presented that these soluble forms are derived proteolytically from the cell surface forms, (Nophar et al., 1990; Porteu and Nathan, 1990; Porteu et al., 1991).

The claimed invention is summarized at page 3 of the specification as follows:

The present invention provides a method of modulating signal transduction and/or cleavage in tumor necrosis factor receptors (TNF-Rs) comprising interfering with one or more amino acids in the sequence of a TNF-R or with an effector protein interacting with the TNF-R.

This interference influences the normal functioning of the TNF-Rs or influences an effector protein interacting therewith, and thereby modulates signal transduction by causing partial or total inhibition thereof, or influences shedding, i.e. abolishes cleavage of the soluble form of the receptor.

The present invention further provides peptides or other molecules which interact either with the receptor itself, i.e. interact with one or more amino acids in the receptor sequence, or interact with the effector proteins, and thus modulate the normal functioning of the TNF-Rs. The above molecules also include antibodies or fragments thereof.

Appellants have found the role certain amino acids of human p55 TNF-R have in determining how the receptor functions. For example, appellants have found that

transfectants expressing mutant receptors with deletion of the intercellular amino acids 405-426 were not responsive to antibodies against the human p55 TNF-R¹ (specification, page 6). Appellants state at page 7 of the specification that mutant receptors having amino acids 415-426 deleted confer to the transfected cells high responsiveness to cytotoxic antibodies against the human p55 TNF-R. Appellants go on to say in the third and fourth paragraph on page 7 of the specification that:

In a third mutant, a single serine residue (amino acid 197) in the transmembrane domain was exchanged by site directed mutagenesis against alanine, an amino acid said to be compatible with all known secondary structures of amino acid sequences. Functional analysis of cells transfected with this receptor mutant revealed a significant impairment in these receptors to trigger cell death in response to mimetic antibodies against the human p55 TNF-R. Yet this functional disruption was not complete and a small cytotoxic effect could still be observed.

Yet, other mutants, in which either amino acids 170-174, 175-179 or both, i.e., amino acids 170-179 were deleted, abolished shedding of the soluble extracellular forms of the receptor. This finding demonstrates that the region of amino acids 170-179 or part thereof, of the receptor, which lies just outside the transmembrane domain, must be intact in order to allow formation of the soluble TNF receptors. Therefore, any interference with this region, or the effector protein interacting therewith, will abolish shedding. The effector protein, in this case, is believed to be a proteolytic enzyme.

For the purposes of considering the issues raised in this appeal, we believe the claims should be considered in two groups which we will denominate the use claims and the screening claims. Claims 34 through 36, 42, 44, 47, 48-50, 56, and 60 are the use claims. Claims 37, 38, 40, 43, 51, 52, and 54 are the screening claims. As can be seen,

¹ Appellants explain at page 6 of the specification that monoclonal antibodies against the human p55 TNF-R mimic TNF action.

claim 37 is directed to a method for identifying molecules which interact with TNF-R to modulate signal transduction. The method comprises three steps: (1) preparing a specified target peptide, (2) screening peptide libraries and/or broth of biological matter with the target peptide and identifying any molecules which bind to the target peptide and (3) screening any molecules identified in the second step for their ability to modulate signal transduction of TNF-R to identify any molecule which tests positive for such signal transduction modulation. As can be seen, claim 37 does not require that any molecule be actually identified.

The use claims however do require the presence and use of a molecule which interacts with a specified portion of TNF-R. For example, claim 34 requires identification of a specific molecule and bringing that molecule into contact with a specified portion of TNF-R.

Discussion

We start our analysis with the proposition that the examiner bears the initial burden of providing reasons why the supporting disclosure does not enable a claim. In re Marzocchi, 439 F.2d 220, 223, 169 USPQ 367, 369 (CCPA 1971). In reviewing the examiner's statement of the rejection on pages 3-5 of the Answer, we find the examiner is concerned that the specification does not set forth "one example of an agent that binds to the TNF-R at any set of amino acids or those amino acids set forth in Claims [sic] or its effector protein." The examiner also states at page 4 of the Answer that "it is not predictable what the agent is that will stabilize the TNF-R or will bind an effector protein to

TNF-R, to blunt its signal transduction because there is not guidance in the specification as to what the characteristics of this (these) agent is.” The examiner also questions the identity of the “effector protein” which forms part of the present invention. The examiner concludes at page 5 of the Answer that “it would require undue experimentation for one of ordinary skill in the art to use the method claimed because no guidance is provided in the specification as to what agents will be useful for modulating signal transduction by binding the TNF-R or by binding to an effector protein that interacts with the TNF-R.”

It is difficult to review the examiner’s rejection as expressed in the Answer because the examiner has not addressed the requirements of any individual claim on appeal. While certain of the examiner’s statements may be correlated to the requirements of some of the claims on appeal, and in responding to appellants’ arguments presented in their Appeal Brief, the examiner has further elaborated her position, we do not have a precise, coherent statement why any single claim on appeal is unpatentable.

Turning first to the screening claims, we find that this aspect of the rejection can be easily decided. As seen from representative claim 37, the claimed method does not require that molecules which interact with TNF-R to modulate signal transduction by the TNF-R be actually identified. The examiner argues at page 11 of the Answer that step c) of claim 37 was “not an optional step.” However, the examiner has lost sight of the fact that step b) of claim 37 only requires a screening step to identify any molecules which bind to the target peptide. Step c) only requires further screening if any molecules are identified in step b). It may be that the material screened in screening step b) of claim 37 will not

contain the specified molecules which bind to the target peptide. If so, then step c) would not be performed. That situation does not mean that claim 37 as whole is non-enabled. The examiner has not explained why the claimed screening methods would not identify the defined molecules if they are present in the material being screened.

By way of analogy, let us consider a claim directed to separating iron scrap from a waste stream by use of magnets. The fact that the waste streams processed according to that method may never contain iron scrap does not mean that the method is non-enabled.

The use claims stand on another foot in that they presuppose the screening procedure has successfully identified molecules which bind according to the claims on appeal. As we understand the examiner's position it is premised in large part upon the fact that the specification of this application does not describe a specific molecule which possesses the binding requirements of the claims on appeal. However, the lack of description of a single specific molecule does not in and of itself mean that the claims are non-enabled. Rather, the specification need only teach one skilled in the art how to practice the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561-62, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993). In considering the issue of undue experimentation in PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558, 1564, 37 USPQ2d 1618, 1623 (Fed. Cir. 1996), the court stated:

In unpredictable art areas, this court has refused to find broad generic claims enabled by specifications that demonstrate the enablement of only one or a few embodiments and do not demonstrate with reasonable specificity how to make and use other potential embodiments across the full scope of the claim. See, e.g., In re Goodman, 11 F.3d 1046, 1050-52, 29 USPQ2d

2010, 2013-15 (Fed. Cir. 1993); Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1212-14, 18 USPQ2d 1016, 1026-28 (Fed. Cir.), cert. denied, 502 U.S. 856 (1991); In re Vaeck, 947 F.2d at 496, 20 USPQ2d at 1445. Enablement is lacking in those cases, the court has explained, because the undescribed embodiments cannot be made, based on the disclosure in the specification, without undue experimentation. But the question of undue experimentation is a matter of degree. The fact that some experimentation is necessary does not preclude enablement; what is required is that the amount of experimentation “must not be unduly extensive.” Atlas Powder Co., v. E.I. DuPont De Nemours & Co., 750 F.2d 1569, 1576, 224 USPQ 409, 413 (Fed. Cir. 1984). The Patent and Trademark Office Board of Appeals summarized the point well when it stated:

The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the invention claimed.

Ex parte Jackson, 217 USPQ 804, 807 (1982).

To the extent the examiner is concerned that the claims may contain so-called “inoperative” embodiments, the court discussed this concern in Atlas Powder Co. v. E.I. du Pont de Nemours & Co., 750 F.2d 1569, 1576-77, 224 USPQ 409, 414 (Fed. Cir. 1984), stating:

Even if some of the claimed combinations were inoperative, the claims are not necessarily invalid. “It is not a function of the claims to specifically exclude . . . possible inoperative substances” In re Dinh-Nguyen, 492 F.2d 856, 859-59, 181 USPQ 46, 48 (CCPA 1974) (emphasis omitted). Accord, In re Geerdes, 491 F.2d 1260, 1265, 180 USPQ 789, 793 (CCPA 1974); In re Anderson, 471 F.2d 1237, 1242, 176 USPQ 331, 334-35 (CCPA 1971). Of course, if the number of inoperative combinations becomes significant, and in effect forces one of ordinary skill in the art to experiment unduly in order to practice the claimed invention, the claims might indeed be invalid. See, e.g., In re Cook, 439 F.2d 730, 735, 169 USPQ 298, 302 (CCPA 1971).

Absent a fact-based explanation from the examiner why the experimentation required to practice the methods set forth in the use claims on appeal would be undue rather than routine, we conclude that the examiner has not established a prima facie case of lack of enablement.

The examiner's rejection is reversed.

Other Issues

1. p75-TNF-R.

As explained above, the present invention involves two distinct tumor necrosis factor receptors, i.e., p55-TNF-R and p75-TNF-R. The vast majority of the disclosure in this application is directed to the p55 receptor. The most illuminating discussion of the p75 receptor in the specification appears at page 29 where appellants state:

Although reference is made throughout to the p55-TNF-R, it is evident from what is known of the p75-TNF-R, that it functions similarly. Therefore the present invention encompasses modulation of the signal transduction and/or cleavage in both known TNF receptors.

Some of the claims on appeal contain an embodiment directed to the p75-TNF-R. For example, claim 34 first references a molecule which binds to the portion of TNF-R which includes certain amino acids of human p55-TNF-R or "the corresponding amino acids of the human p75-TNF-R." It does not appear from the record that the examiner has paid attention to this alternative embodiment.

Upon return of the application, the examiner should review all of the claims pending and ensure that the subject matter of each claim has been fully examined. For example,

the examiner should pay special attention to that aspect of the claimed subject matter directed to p75-TNF-R in terms of claim definiteness and enablement. It may not be clear from claims, such as claim 34, which amino acids of the p75-TNF-R correspond to the p55-TNF-R amino acids recited in that claim in that it is not clear what appellants mean by use of the word “correspond.” Correspond in identity? Location in the protein? Assuming one skilled in the art would understand which amino acids “correspond” between the two receptors, the question becomes would one be able to practice the claimed invention in regard to the p75-TNF-R embodiment without undue experimentation? In considering this issue, the examiner should take into account the legal standards set forth above. If the examiner decides an enablement question does arise in regard to this aspect to the claimed invention or any other aspect of the claims on appeal, we urge the examiner to review the court’s opinion in Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 52 USPQ2d 1129 (Fed. Cir. 1999) since the court provided a model of a fact-based analysis of an enablement issue using the so-called Wands factors. See In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). In the future, it would be helpful to the record in patent applications if the examiner would consider enablement issues in the context of the Wands factors and make of record a fact-based analysis of the relevant factors.

The decision of the examiner is reversed.

REVERSED

Appeal No. 1999-0197
Application 08/054,970

William F. Smith
Administrative Patent Judge

Toni R. Scheiner
Administrative Patent Judge

Demetra J. Mills
Administrative Patent Judge

)
)
)
)
) BOARD OF PATENT
) APPEALS AND
)
) INTERFERENCES
)
)
)

Appeal No. 1999-0197
Application 08/054,970

Roger L. Browdy
Browdy and Neimark
419 Seventh Street, NW
Washington, DC 20004